[go: up one dir, main page]

AR056202A1 - Nucleosidos modificados en 4' como agentes antivirales - Google Patents

Nucleosidos modificados en 4' como agentes antivirales

Info

Publication number
AR056202A1
AR056202A1 ARP060104218A ARP060104218A AR056202A1 AR 056202 A1 AR056202 A1 AR 056202A1 AR P060104218 A ARP060104218 A AR P060104218A AR P060104218 A ARP060104218 A AR P060104218A AR 056202 A1 AR056202 A1 AR 056202A1
Authority
AR
Argentina
Prior art keywords
nhr4
optionally substituted
value
unsubstituted
nr4nh2
Prior art date
Application number
ARP060104218A
Other languages
English (en)
Inventor
Jinfa Du
Phillip Furman
Michael Sofia
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Publication of AR056202A1 publication Critical patent/AR056202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos, métodos y composiciones para tratar un huésped infectado con virus de inmunodeficiencia humana y virus de hepatitis B, método que comprende administrar una cantidad efectiva de un 4'-C-substituido-b-D- y b-L-nucleosido o una sal o prodroga farmacéuticamente aceptable del mismo. Reivindicacion 1: Un compuesto caracterizado porque comprende un b-D- y b-L-nucleosido o una sal o prodroga farmacéuticamente aceptable del mismo, que tiene una estructura definida por la formula (1) o por la formula (2), donde X es hidrogeno, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S(O)bR4, OH, OR4, N3, CN, o CF3; Y es hidrogeno, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S(O)bR4, OH, OR4, N3, CN, CF3, hidroximetilo, metilo, etilo opcionalmente substituido o no substituido, vinilo opcionalmente substituido o no substituido, 2-bromovinilo opcionalmente substituido o no substituido, etinilo opcionalmente substituido o no substituido; R1 es F o N3; R2 es OH, OR4, OC(O)R4, OPvO3vMxR4yR5z, PvO3vMxR4yR5z, OCH2PvO3vMxR4yR5z, OP(O)(OQ)a(NHR4)b, SH, SR4, S(O)bR4, SC(O)R4, NH2, NHC(O)R4, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4; R3 es F, ciano, azido, etinilo, clorovinilo, fluorovinilo, alquilo C1-6, alquilo C1-6 substituido con uno a tres átomos de halogeno, alquenilo C1-6 o alquinilo C1-6 con la condicion que cuando R1 es N3, entonces R3 no es hidroximetilo; Z es O, S, CH2 o C=CH2; A es N, CH, o CF; y R4 y R5 son iguales o diferentes y son alquilo inferior, alquenilo inferior, acilo de 1-17 átomos de carbono, arilo, o aralquilo; M es al menos un miembro seleccionado del grupo formado por H+, Na+, y K+; v tiene un valor de 1, 2, o 3; x, y, y z son independientes entre sí y tienen un valor de 0, 1, 2, 3 o 4; y a tiene un valor de 0 o 1, b tiene un valor de 1 o 2, y Q es M o R4.
ARP060104218A 2005-09-26 2006-09-27 Nucleosidos modificados en 4' como agentes antivirales AR056202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72038805P 2005-09-26 2005-09-26

Publications (1)

Publication Number Publication Date
AR056202A1 true AR056202A1 (es) 2007-09-26

Family

ID=37900393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104218A AR056202A1 (es) 2005-09-26 2006-09-27 Nucleosidos modificados en 4' como agentes antivirales

Country Status (17)

Country Link
US (1) US8569478B2 (es)
EP (2) EP3159351A3 (es)
JP (1) JP2009510075A (es)
KR (1) KR20080065272A (es)
CN (2) CN101310021A (es)
AR (1) AR056202A1 (es)
AU (1) AU2006294807B2 (es)
BR (1) BRPI0616738A2 (es)
CA (2) CA2623522C (es)
EA (1) EA200800932A1 (es)
ES (1) ES2617582T3 (es)
IL (1) IL190390A0 (es)
NZ (3) NZ609146A (es)
PT (1) PT1937825T (es)
UY (1) UY29868A1 (es)
WO (1) WO2007038507A2 (es)
ZA (1) ZA200802723B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
PT2604620T (pt) 2003-05-30 2016-08-18 Gilead Pharmasset Llc Analogos de nucleósido fluorados modificados
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CA2782524A1 (en) * 2009-12-17 2011-06-23 Novadex Pharmaceuticals Ab 3'-deoxy-3'-methylidene-.beta.-l-nucleosides
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
PE20141056A1 (es) 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
MX355708B (es) 2012-05-22 2018-04-27 Idenix Pharmaceuticals Llc Compuestos de d-aminoacidos para enfermedades del higado.
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2852583A1 (en) 2012-05-23 2015-04-01 Bristol-Myers Squibb Company Sulfilimine and sulphoxide methods for producing festinavir
AP3545A (en) 2012-05-25 2016-01-14 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
MX351816B (es) 2013-01-31 2017-10-30 Gilead Pharmasset Llc Formulacion de combinacion de dos compuestos antivirales.
EP2970358B1 (en) 2013-03-04 2021-06-30 Idenix Pharmaceuticals LLC 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US20160060252A1 (en) 2013-04-16 2016-03-03 Bristol-Myers Squibb Company 5-methyluridine method for producing festinavir
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3008060A1 (en) 2013-06-13 2016-04-20 Bristol-Myers Squibb Company Tert-butyl-sulphoxide method for producing festinavir
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
MX2016004558A (es) 2013-10-11 2016-07-06 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
KR101718242B1 (ko) * 2015-11-25 2017-03-21 주식회사 타미온 Hiv 억제 활성을 가지는 신규한 화합물 및 이의 용도
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP4483875A2 (en) 2016-05-10 2025-01-01 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN111995649A (zh) * 2020-04-09 2020-11-27 瀚海新拓(杭州)生物医药有限公司 一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途
CN113501853B (zh) * 2021-09-13 2021-12-07 南京颐媛生物医学研究院有限公司 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途
EP4431100A4 (en) * 2021-11-12 2025-01-15 Univ Hokkaido Nat Univ Corp ANTIVIRAL AGENT

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
ZA867013B (en) 1985-09-17 1988-04-27 Wellcome Found Therapeutic nucleosides
EP0332626A1 (en) 1986-11-21 1989-09-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions for treating viral infections in humans
DE3739366A1 (de) * 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
AU2526188A (en) 1987-09-22 1989-04-18 Regents Of The University Of California, The Liposomal nucleoside analogues for treating aids
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
AU7623991A (en) 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5817799A (en) * 1990-07-23 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5414078A (en) * 1991-04-05 1995-05-09 Emory University Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors
WO1993000910A1 (en) 1991-07-12 1993-01-21 Vical, Inc. Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
EP0746319A4 (en) 1993-05-12 1997-11-05 Karl Y Hostetler ACYCLOVIR DERIVATIVES FOR TOPICAL USE
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
DE19632823C1 (de) * 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
FI107059B (fi) * 1998-07-01 2001-05-31 Metso Paper Inc Paperikoneen formeri-puristinosa ja menetelmä rainan siirtämiseksi formerilta puristinosalle
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
JP2005503358A (ja) 2001-06-22 2005-02-03 フアーマセツト・リミテツド β−２’−または３’−ハロヌクレオシド
WO2005011709A1 (en) * 2003-02-19 2005-02-10 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
PT2604620T (pt) 2003-05-30 2016-08-18 Gilead Pharmasset Llc Analogos de nucleósido fluorados modificados
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents

Also Published As

Publication number Publication date
EP3159351A2 (en) 2017-04-26
EP3159351A3 (en) 2017-05-17
WO2007038507A2 (en) 2007-04-05
WO2007038507A3 (en) 2007-09-13
KR20080065272A (ko) 2008-07-11
NZ567272A (en) 2012-02-24
CN101310021A (zh) 2008-11-19
ES2617582T3 (es) 2017-06-19
NZ609146A (en) 2014-08-29
AU2006294807A1 (en) 2007-04-05
PT1937825T (pt) 2017-03-08
CA2623522A1 (en) 2007-04-05
JP2009510075A (ja) 2009-03-12
CA2904692A1 (en) 2007-04-05
BRPI0616738A2 (pt) 2011-06-28
EP1937825B1 (en) 2016-12-21
EP1937825A4 (en) 2010-06-23
EP1937825A2 (en) 2008-07-02
ZA200802723B (en) 2009-03-25
CN102924549A (zh) 2013-02-13
AU2006294807B2 (en) 2013-01-17
CA2623522C (en) 2015-12-08
IL190390A0 (en) 2008-11-03
US8569478B2 (en) 2013-10-29
EA200800932A1 (ru) 2008-10-30
NZ597544A (en) 2013-04-26
UY29868A1 (es) 2007-04-30
US20110021454A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
AR056202A1 (es) Nucleosidos modificados en 4' como agentes antivirales
RU2358979C2 (ru) Модифицированные фторированные аналоги нуклеозида
CY1121639T1 (el) Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων
JP2015535261A5 (es)
HN2006041184A (es) Metodos y estuches para dosificar nucleosidos antivirales beta-d-2 3- didehydro-2 , 3-dideoxy 5- fluorocytidina
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
CL2011002859A1 (es) Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c.
PE20130151A1 (es) Sintesis estereoselectiva de activos que contienen fosforo
AR054475A1 (es) Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion
AR040474A1 (es) Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
RS51725B (en) N-METHYLAMINOMETHYL ISOINDOL COMPOUNDS AND COMPOSITIONS CONTAINING THEM AND USING THE SAME
DK2097434T3 (da) Nukleosidarylphosphoramidater og deres anvendelse som antivirale midler til behandlingen af hepatitis C virus
RU2651892C3 (ru) Нуклеозидфосфорамидаты в качестве противовирусных агентов
JP2011520815A5 (es)
BR0317094A (pt) Sal de alumìnio livre de zircÈnio, e, composição antiperspirante
EA200970375A1 (ru) Соединения и способы лечения вируса гепатита с
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
AR075396A1 (es) Derivados de quinazolinas y composiciones farmaceuticas
RU2010140627A (ru) Производные пирролидина

Legal Events

Date Code Title Description
FB Suspension of granting procedure